NCT00488384

Acitretin Plasma Levels Under Hemodialysis

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Günther Hofbauer · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.

Detailed description

Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined. * Trial with medicinal product

Conditions

• Carcinoma, Squamous Cell

Interventions

Type	Name	Description
DRUG	Chemopreventive application (Acitretin)	Chemopreventive application (Acitretin)

Timeline

• Start date: 2007-06-01
• Primary completion: 2014-12-01
• Completion: 2018-06-01
• First posted: 2007-06-20
• Last updated: 2018-07-19

Locations

1 site across 1 country: Switzerland